Tofersen Offers Lasting Benefit for SOD1 Amyotrophic Lateral Sclerosis

TUESDAY, Jan. 6, 2026-- Tofersen shows long-term benefits for patients with SOD1 amyotrophic lateral sclerosis (ALS), according to a study published online Dec. 22 in JAMA Neurology.Timothy M. Miller, M.D., from the Washington University School of...